Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials
Lysophosphatidic acid (LPA) is a bioactive lipid mediator primarily derived from membrane phospholipids. LPA initiates cellular effects upon binding to a family of G protein-coupled receptors, termed LPA receptors (LPAR1 to LPAR6). LPA signaling drives cell migration and proliferation, cytokine prod...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/7/1629 |
| _version_ | 1797528392908668928 |
|---|---|
| author | Yu-Hsuan Lin Yueh-Chien Lin Chien-Chin Chen |
| author_facet | Yu-Hsuan Lin Yueh-Chien Lin Chien-Chin Chen |
| author_sort | Yu-Hsuan Lin |
| collection | DOAJ |
| description | Lysophosphatidic acid (LPA) is a bioactive lipid mediator primarily derived from membrane phospholipids. LPA initiates cellular effects upon binding to a family of G protein-coupled receptors, termed LPA receptors (LPAR1 to LPAR6). LPA signaling drives cell migration and proliferation, cytokine production, thrombosis, fibrosis, angiogenesis, and lymphangiogenesis. Since the expression and function of LPA receptors are critical for cellular effects, selective antagonists may represent a potential treatment for a broad range of illnesses, such as cardiovascular diseases, idiopathic pulmonary fibrosis, voiding dysfunctions, and various types of cancers. More new LPA receptor antagonists have shown their therapeutic potentials, although most are still in the preclinical trial stage. This review provided integrative information and summarized preclinical findings and recent clinical trials of different LPA receptor antagonists in cancer progression and resistance. Targeting LPA receptors can have potential applications in clinical patients with various diseases, including cancer. |
| first_indexed | 2024-03-10T09:57:42Z |
| format | Article |
| id | doaj.art-57d530c8c1d04362b00dea966193fd76 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T09:57:42Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-57d530c8c1d04362b00dea966193fd762023-11-22T02:12:05ZengMDPI AGCells2073-44092021-06-01107162910.3390/cells10071629Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and TrialsYu-Hsuan Lin0Yueh-Chien Lin1Chien-Chin Chen2Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 804, TaiwanDepartment of Life Science, National Taiwan University, Taipei 106, TaiwanDepartment of Pathology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 600, TaiwanLysophosphatidic acid (LPA) is a bioactive lipid mediator primarily derived from membrane phospholipids. LPA initiates cellular effects upon binding to a family of G protein-coupled receptors, termed LPA receptors (LPAR1 to LPAR6). LPA signaling drives cell migration and proliferation, cytokine production, thrombosis, fibrosis, angiogenesis, and lymphangiogenesis. Since the expression and function of LPA receptors are critical for cellular effects, selective antagonists may represent a potential treatment for a broad range of illnesses, such as cardiovascular diseases, idiopathic pulmonary fibrosis, voiding dysfunctions, and various types of cancers. More new LPA receptor antagonists have shown their therapeutic potentials, although most are still in the preclinical trial stage. This review provided integrative information and summarized preclinical findings and recent clinical trials of different LPA receptor antagonists in cancer progression and resistance. Targeting LPA receptors can have potential applications in clinical patients with various diseases, including cancer.https://www.mdpi.com/2073-4409/10/7/1629antagonistcancerclinical triallysophosphatidic acidlysophosphatidic receptortherapy |
| spellingShingle | Yu-Hsuan Lin Yueh-Chien Lin Chien-Chin Chen Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials Cells antagonist cancer clinical trial lysophosphatidic acid lysophosphatidic receptor therapy |
| title | Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials |
| title_full | Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials |
| title_fullStr | Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials |
| title_full_unstemmed | Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials |
| title_short | Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials |
| title_sort | lysophosphatidic acid receptor antagonists and cancer the current trends clinical implications and trials |
| topic | antagonist cancer clinical trial lysophosphatidic acid lysophosphatidic receptor therapy |
| url | https://www.mdpi.com/2073-4409/10/7/1629 |
| work_keys_str_mv | AT yuhsuanlin lysophosphatidicacidreceptorantagonistsandcancerthecurrenttrendsclinicalimplicationsandtrials AT yuehchienlin lysophosphatidicacidreceptorantagonistsandcancerthecurrenttrendsclinicalimplicationsandtrials AT chienchinchen lysophosphatidicacidreceptorantagonistsandcancerthecurrenttrendsclinicalimplicationsandtrials |